Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Research Article

Examining the Mechanism of Treatment for Primary Dysmenorrhea with Wenjing Huoxue Decoction based on Transcriptomics, Metabolomics, and Network Pharmacology

Author(s): Weisen Fan, Dandan Wang*, Liwei Yan and Zheng Yuan

Volume 30, Issue 22, 2024

Published on: 24 May, 2024

Page: [1771 - 1785] Pages: 15

DOI: 10.2174/0113816128295774240523062258

Price: $65

Abstract

Background: Wenjing Huoxue Decoction (WJHXD) is a traditional treatment for primary dysmenorrhea (PD) that can quickly relieve various symptoms caused by PD. Previous clinical studies have shown that WJHXD has better long-term efficacy than ibuprofen in the treatment of PD and can reverse the disorder of T cell subsets.

Objective: To investigate the effect of WJHXD on serum-related factors in the treatment of PD, including the identification of key targets, pathways, and active ingredients.

Methods: In order to study the effects of the WJHXD intervention in Parkinson's Disease (PD) rats, we used transcriptomics and metabolomics methods to examine the differentially expressed genes (DEGs) and differentially expressed metabolites (DEMs). We also utilized network pharmacology to predict the target and effective route of WJHXD in treating PD. Finally, we employed molecular docking (MD) technology to confirm the placement of important targets and metabolites.

Results: WJHXD has been found to be effective in prolonging the onset time and decreasing the number of writhing episodes in PD rats after oxytocin injection. It has also been observed to reduce the levels of PGF2, COX-2, AVP, and PGE2 in the serum of PD rats to different degrees. Transcriptomics analysis has revealed that the core targets of WJHXD include KRT1, KRT16, CCL5, F2, NOS2, RAC2, and others, while the core pathways are Calcium signaling and cAMP signaling. The Estrogen signaling pathway was found to be downregulated in PD rats compared to normal uterine tissue, but WJHXD was able to up-regulate the pathway. A combined transcriptomics and metabolomics analysis suggested that WJHXD may be involved in eight metabolism-related pathways, with the most reliable ones being mucin-type O-glycan biosynthesis and glycolysis or gluconeogenesis. MD has shown that Hydroxyisocaproic acid may bind to important targets such as SLC6A4, PTGER3, IGFBP3, and IGF2.

Conclusion: In WJHXD, the most targeted herbs were Corydalis rhizoma, licorice, and Myrrha. The most targeted active ingredients include quercetin, 3'-Hydroxy-4'-O-methylglabridin, shinpterocarpin, and isorhamnetin. Potential targets include PTGS2, NOS2, AR, SCN5A, and GAS6. Analysis revealed 72 highly reliable relationships between group A and B DEGs and DEMs, with 23 positive correlations and 49 negative correlations among them. A combined analysis of transcriptomics, metabolomics, and network pharmacology was used to identify possible targets, pathways, and active ingredients of WJHXD in PD treatment, and the correlation between DEGs and DEMs was investigated. However, further research is required to confirm the relationship between active ingredients, targets, and metabolites.

« Previous
[1]
Low I, Wei SY, Lee PS, et al. Neuroimaging studies of primary dysmenorrhea. Adv Exp Med Biol 2018; 1099: 179-99.
[http://dx.doi.org/10.1007/978-981-13-1756-9_16] [PMID: 30306525]
[2]
Ferries-Rowe E, Corey E, Archer JS. Primary dysmenorrhea. Obstet Gynecol 2020; 136(5): 1047-58.
[http://dx.doi.org/10.1097/AOG.0000000000004096] [PMID: 33030880]
[3]
Ryan SA. The treatment of dysmenorrhea. Pediatr Clin North Am 2017; 64(2): 331-42.
[http://dx.doi.org/10.1016/j.pcl.2016.11.004] [PMID: 28292449]
[4]
Almanasef M, Alqarni H. Self-care strategies for the management of primary dysmenorrhea among young women in Asir region, Saudi Arabia: A cross-sectional study. Eur Rev Med Pharmacol Sci 2023; 27(1): 172-8.
[http://dx.doi.org/10.26355/eurrev_202301_30869] [PMID: 36647866]
[5]
Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: A critical review. Hum Reprod Update 2015; 21(6): 762-78.
[http://dx.doi.org/10.1093/humupd/dmv039] [PMID: 26346058]
[6]
Oladosu FA, Tu FF, Hellman KM. Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: Epidemiology, causes, and treatment. Am J Obstet Gynecol 2018; 218(4): 390-400.
[http://dx.doi.org/10.1016/j.ajog.2017.08.108] [PMID: 28888592]
[7]
Basciani S, Porcaro G. Counteracting side effects of combined oral contraceptives through the administration of specific micronutrients. Eur Rev Med Pharmacol Sci 2022; 26(13): 4846-62.
[http://dx.doi.org/10.26355/eurrev_202207_29210] [PMID: 35856377]
[8]
Chen B, Guo Q, Zhang Q, Di Z, Zhang Q. Revealing the central mechanism of acupuncture for primary dysmenorrhea based on neuroimaging: A narrative review. Pain Res Manag 2023; 2023: 1-8.
[http://dx.doi.org/10.1155/2023/8307249] [PMID: 36852393]
[9]
Gao L, Jia C, Zhang H, Ma C. Wenjing decoction (herbal medicine) for the treatment of primary dysmenorrhea: A systematic review and meta-analysis. Arch Gynecol Obstet 2017; 296(4): 679-89.
[http://dx.doi.org/10.1007/s00404-017-4485-7] [PMID: 28791471]
[10]
Wang D, Wang D, Cai P, Meng Y, Zhai F. Clinical effect of warming menstruation and removing stasis to relieve pain on primary dysmenorrhea and its regulation mechanism on T cell subsets. Chin J Exp Tradit Med Form 2020; 26: 94-9.
[http://dx.doi.org/10.13422/j.cnki.syfjx.20201963]
[11]
Wang D, Wang D, Zhang Y, Zhai F, Cai P, Ma Q. To explore the mechanism of treating primary dysmenorrhea with cold coagulation and blood stasis syndrome by Warming Jing Huoxue decoction based on nerve growth factor. Tradit Chin Drug Res Pharmacol 2021; 32: 1468-73.
[http://dx.doi.org/10.19378/j.issn.1003-9783.2021.10.008]
[12]
Fan W, Zhang Y, Wang D, Wang C, Yang J. The impact of Yiwei decoction on the LncRNA and CircRNA regulatory networks in premature ovarian insufficiency. Heliyon 2023; 9(9): e20022.
[http://dx.doi.org/10.1016/j.heliyon.2023.e20022] [PMID: 37809621]
[13]
Ma W, Wang M, Wang ZQ, et al. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 2010; 19(10): 2445-52.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0565] [PMID: 20805315]
[14]
Li J, Xu C, Zhang J, et al. Identification of miRNA-target gene pairs in the parietal and frontal lobes of the brain in patients with Alzheimer’s disease using bioinformatic analyses. Neurochem Res 2021; 46(4): 964-79.
[http://dx.doi.org/10.1007/s11064-020-03215-8] [PMID: 33586092]
[15]
Cui L, Lu H, Lee YH. Challenges and emergent solutions for LC-MS/MS based untargeted metabolomics in diseases. Mass Spectrom Rev 2018; 37(6): 772-92.
[http://dx.doi.org/10.1002/mas.21562] [PMID: 29486047]
[16]
French WR, Zimmerman LJ, Schilling B, et al. Wavelet-based peak detection and a new charge inference procedure for MS/MS implemented in ProteoWizard’s msConvert. J Proteome Res 2015; 14(2): 1299-307.
[http://dx.doi.org/10.1021/pr500886y] [PMID: 25411686]
[17]
Mahieu NG, Genenbacher JL, Patti GJ. A roadmap for the XCMS family of software solutions in metabolomics. Curr Opin Chem Biol 2016; 30: 87-93.
[http://dx.doi.org/10.1016/j.cbpa.2015.11.009] [PMID: 26673825]
[18]
Howe C, Alshehri A, Muggeridge D, et al. Untargeted metabolomics profiling of an 80.5 km simulated treadmill ultramarathon. Metabolites 2018; 8(1): 14.
[http://dx.doi.org/10.3390/metabo8010014] [PMID: 29438325]
[19]
Kang J, Guo X, Peng H, et al. Metabolic implications of amino acid metabolites in chronic kidney disease progression: A metabolomics analysis using OPLS-DA and MBRole2.0 database. Int Urol Nephrol 2023; 56(3): 1173-84.
[http://dx.doi.org/10.1007/s11255-023-03779-8] [PMID: 37728808]
[20]
Li X, Wei S, Niu S. Network pharmacology prediction and molecular docking-based strategy to explore the potential mechanism of Huanglian Jiedu decoction against sepsis. Comput Biol Med 2022; 144: 105389.
[http://dx.doi.org/10.1016/j.compbiomed.2022.105389]
[21]
Huang Z, Yang Y, Fan X, Ma W. Network pharmacology-based investigation and experimental validation of the mechanism of scutellarin in the treatment of acute myeloid leukemia. Front Pharmacol 2022; 13: 952677.
[http://dx.doi.org/10.3389/fphar.2022.952677] [PMID: 36160389]
[22]
Wang L, Liu Y, Shen G, He G, Qiu S, Li B. Mechanisms of Si-Wu decoction in the treatment of ulcerative colitis revealed by network pharmacology and experimental verification. J Ethnopharmacol 2023; 317: 116847.
[http://dx.doi.org/10.1016/j.jep.2023.116847] [PMID: 37356743]
[23]
Shang L, Wang Y, Li J. Mechanism of Sijunzi decoction in the treatment of colorectal cancer based on network pharmacology and experimental validation. J Ethnopharmacol 2023; 302(Pt A): 115876.
[http://dx.doi.org/10.1016/j.jep.2022.115876]
[24]
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102(43): 15545-50.
[http://dx.doi.org/10.1073/pnas.0506580102] [PMID: 16199517]
[25]
Hu E, Ding R, Li T, et al. Temporal metabolomic alteration in rat brains of experimental intracerebral hemorrhage. Brain Res Bull 2021; 170: 234-45.
[http://dx.doi.org/10.1016/j.brainresbull.2021.02.021] [PMID: 33631271]
[26]
Duangnumsawang Y, Zentek J, Vahjen W, Tarradas J, Goodarzi Boroojeni F. Alterations in bacterial metabolites, cytokines, and mucosal integrity in the caecum of broilers caused by feed additives and host-related factors. Front Physiol 2022; 13: 935870.
[http://dx.doi.org/10.3389/fphys.2022.935870] [PMID: 36171972]
[27]
Wang Y, Yuan Y, Wang W, et al. Mechanisms underlying the therapeutic effects of Qingfeiyin in treating acute lung injury based on GEO datasets, network pharmacology and molecular docking. Comput Biol Med 2022; 145: 105454.
[http://dx.doi.org/10.1016/j.compbiomed.2022.105454] [PMID: 35367781]
[28]
Guo B, Zhao C, Zhang C, et al. Elucidation of the anti-inflammatory mechanism of Er Miao San by integrative approach of network pharmacology and experimental verification. Pharmacol Res 2022; 175: 106000.
[http://dx.doi.org/10.1016/j.phrs.2021.106000] [PMID: 34838694]
[29]
Zhang M, Zhang X, Pei J, et al. Identification of phytochemical compounds of Fagopyrum dibotrys and their targets by metabolomics, network pharmacology and molecular docking studies. Heliyon 2023; 9(3): e14029.
[http://dx.doi.org/10.1016/j.heliyon.2023.e14029] [PMID: 36911881]
[30]
Zou J, Xu W, Li Z, et al. Network pharmacology-based approach to research the effect and mechanism of Si-Miao-Yong-An decoction against thromboangiitis obliterans. Ann Med 2023; 55(1): 2218105.
[http://dx.doi.org/10.1080/07853890.2023.2218105] [PMID: 37318081]
[31]
Shi X, Li L, Liu Z, Wang F, Huang H. Exploring the mechanism of metformin action in Alzheimer’s disease and type 2 diabetes based on network pharmacology, molecular docking, and molecular dynamic simulation. Ther Adv Endocrinol Metab 2023; 14: 20420188231187493.
[http://dx.doi.org/10.1177/20420188231187493] [PMID: 37780174]
[32]
Zhu W, Li Y, Zhao J, Wang Y, Li Y, Wang Y. The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking. Ann Med 2022; 54(1): 541-52.
[http://dx.doi.org/10.1080/07853890.2022.2034931] [PMID: 35132912]
[33]
Shen ZJ, Fu YB, Hou JL, et al. Integrating network pharmacology, UPLC-Q–TOF–MS and molecular docking to investigate the effect and mechanism of Chuanxiong Renshen decoction against Alzheimer’s disease. Chin Med 2022; 17(1): 143.
[http://dx.doi.org/10.1186/s13020-022-00698-1] [PMID: 36566207]
[34]
Wang X, Wang N, Liang J, Xu Y, Chen G. The effectiveness and safety of acupoint catgut embedding for the treatment of primary dysmenorrhea. Medicine 2020; 99(47): e23222.
[http://dx.doi.org/10.1097/MD.0000000000023222] [PMID: 33217837]
[35]
Kho KA, Shields JK. Diagnosis and management of primary dysmenorrhea. JAMA 2020; 323(3): 268-9.
[http://dx.doi.org/10.1001/jama.2019.16921] [PMID: 31855238]
[36]
French L. Dysmenorrhea in adolescents. Paediatr Drugs 2008; 10(1): 1-7.
[http://dx.doi.org/10.2165/00148581-200810010-00001] [PMID: 18162003]
[37]
Yan L, Fang M, Zhu SJ, et al. Effectiveness and safety of Chinese medicine at shenque (CV 8) for primary dysmenorrhea: A systematic review and meta-analysis of randomized controlled trials. Chin J Integr Med 2023; 29(4): 341-52.
[http://dx.doi.org/10.1007/s11655-022-3319-z] [PMID: 35426052]
[38]
Ma C, Liang N, Gao L, Jia C. Danggui Sini decoction (herbal medicine) for the treatment of primary dysmenorrhoea: A systematic review and meta-analysis. J Obstet Gynaecol 2021; 41(7): 1001-9.
[http://dx.doi.org/10.1080/01443615.2020.1820461] [PMID: 33228406]
[39]
Yang W, Guo H, Niu J, et al. Phloroglucinol inhibits oxytocin-induced contraction in rat gastric circular muscle and uterine smooth muscle. J Obstet Gynaecol 2023; 43(1): 2130208.
[http://dx.doi.org/10.1080/01443615.2022.2130208] [PMID: 36227618]
[40]
Yang M, Chen X, Bo L, et al. Moxibustion for pain relief in patients with primary dysmenorrhea: A randomized controlled trial. PLoS One 2017; 12(2): e0170952.
[http://dx.doi.org/10.1371/journal.pone.0170952] [PMID: 28170396]
[41]
Brown TJ, Barrett N, Meng H, et al. Nonsteroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal hematodiaphyseal dysplasia. Blood 2023; 141(13): 1553-9.
[http://dx.doi.org/10.1182/blood.2022018667] [PMID: 36574346]
[42]
Chai C, Hong F, Yan Y, et al. Effect of traditional Chinese medicine formula GeGen decoction on primary dysmenorrhea: A randomized controlled trial study. J Ethnopharmacol 2020; 261: 113053.
[http://dx.doi.org/10.1016/j.jep.2020.113053] [PMID: 32534120]
[43]
Aguilar HN, Mitchell BF. Physiological pathways and molecular mechanisms regulating uterine contractility. Hum Reprod Update 2010; 16(6): 725-44.
[http://dx.doi.org/10.1093/humupd/dmq016] [PMID: 20551073]
[44]
Chiang YF, Hung HC, Chen HY, et al. The inhibitory effect of extra virgin olive oil and its active compound oleocanthal on prostaglandin-induced uterine hypercontraction and pain-ex vivo and in vivo study. Nutrients 2020; 12(10): 3012.
[http://dx.doi.org/10.3390/nu12103012] [PMID: 33008039]
[45]
Benson JC, Trebak M. Too much of a good thing: The case of SOCE in cellular apoptosis. Cell Calcium 2023; 111: 102716.
[http://dx.doi.org/10.1016/j.ceca.2023.102716] [PMID: 36931194]
[46]
Zhang N, Mao W, Zhang Y, et al. The prostaglandin E2 receptor PTGER2 and prostaglandin F receptor PTGFR mediate oviductal glycoprotein 1 expression in bovine oviductal epithelial cells. J Reprod Dev 2018; 64(2): 101-8.
[http://dx.doi.org/10.1262/jrd.2017-076] [PMID: 29276208]
[47]
Martens JWM, Verhoef-Post M, Abelin N, et al. A homozygous mutation in the luteinizing hormone receptor causes partial Leydig cell hypoplasia: Correlation between receptor activity and phenotype. Mol Endocrinol 1998; 12(6): 775-84.
[http://dx.doi.org/10.1210/mend.12.6.0124] [PMID: 9626653]
[48]
Chen X, Meroueh M, Mazur G, et al. Phenylephrine, a common cold remedy active ingredient, suppresses uterine contractions through cAMP signalling. Sci Rep 2018; 8(1): 11666.
[http://dx.doi.org/10.1038/s41598-018-30094-5] [PMID: 30076382]
[49]
Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011; 7(12): 715-26.
[http://dx.doi.org/10.1038/nrendo.2011.122] [PMID: 21844907]
[50]
Zhang K, Su J, Huang Y, et al. Untargeted metabolomics reveals the synergistic mechanisms of Yuanhu Zhitong oral liquid in the treatment of primary dysmenorrhea. J Chromatogr B Analyt Technol Biomed Life Sci 2021; 1165: 122523.
[http://dx.doi.org/10.1016/j.jchromb.2021.122523] [PMID: 33497845]
[51]
Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 1995; 9(4): 307-12.
[http://dx.doi.org/10.3109/09513599509160464] [PMID: 8629459]
[52]
Hong F, He G, Zhang M, Yu B, Chai C. The establishment of a mouse model of recurrent primary dysmenorrhea. Int J Mol Sci 2022; 23(11): 6128.
[http://dx.doi.org/10.3390/ijms23116128] [PMID: 35682815]
[53]
Wu CC, Huang MY, Kapoor R, Chen CH, Huang YS. Metabolism of omega-6 polyunsaturated fatty acids in women with dysmenorrhea. Asia Pac J Clin Nutr 2008; 17 (Suppl. 1): 216-9.
[PMID: 18296341]
[54]
Bahrami A, Bahrami-Taghanaki H, Khorasanchi Z, et al. Menstrual problems in adolescence: Relationship to serum vitamins A and E, and systemic inflammation. Arch Gynecol Obstet 2020; 301(1): 189-97.
[http://dx.doi.org/10.1007/s00404-019-05343-1] [PMID: 31734759]
[55]
Liu F, Fu J, Bergstrom K, et al. Core 1–derived mucin-type O-glycosylation protects against spontaneous gastritis and gastric cancer. J Exp Med 2020; 217(1): e20182325.
[http://dx.doi.org/10.1084/jem.20182325] [PMID: 31645367]
[56]
Sun R, Yang Y, Lü W, et al. Single-cell transcriptomic analysis of normal and pathological tissues from the same patient uncovers colon cancer progression. Cell Biosci 2023; 13(1): 62.
[http://dx.doi.org/10.1186/s13578-023-01002-w] [PMID: 36944972]
[57]
Itoh K, Akimoto Y, Fuwa TJ, Sato C, Komatsu A, Nishihara S. Mucin-type core 1 glycans regulate the localization of neuromuscular junctions and establishment of muscle cell architecture in Drosophila. Dev Biol 2016; 412(1): 114-27.
[http://dx.doi.org/10.1016/j.ydbio.2016.01.032] [PMID: 26896591]
[58]
Merckx C, Zschüntzsch J, Meyer S, et al. Exploring the therapeutic potential of ectoine in duchenne muscular dystrophy: Comparison with taurine, a supplement with known beneficial effects in the mdx mouse. Int J Mol Sci 2022; 23(17): 9567.
[http://dx.doi.org/10.3390/ijms23179567] [PMID: 36076964]
[59]
Sims NA. Cardiotrophin-like cytokine factor 1 (CLCF1) and neuropoietin (NP) signalling and their roles in development, adulthood, cancer and degenerative disorders. Cytokine Growth Factor Rev 2015; 26(5): 517-22.
[http://dx.doi.org/10.1016/j.cytogfr.2015.07.014] [PMID: 26198769]
[60]
Wen J, Tan D, Li L, Wang X, Pan M, Guo J. RhoA regulates Schwann cell differentiation through JNK pathway. Exp Neurol 2018; 308: 26-34.
[http://dx.doi.org/10.1016/j.expneurol.2018.06.013] [PMID: 29940159]
[61]
Strömberg P, Forsling ML, Akerlund M. Effects of prostaglandin inhibition on vasopressin levels in women with primary dysmenorrhea. Obstet Gynecol 1981; 58(2): 206-8.
[PMID: 7254732]
[62]
Lang CH, Pruznak A, Navaratnarajah M, et al. Chronic α-hydroxyisocaproic acid treatment improves muscle recovery after immobilization-induced atrophy. Am J Physiol Endocrinol Metab 2013; 305(3): E416-28.
[http://dx.doi.org/10.1152/ajpendo.00618.2012] [PMID: 23757407]
[63]
Cameron I, Campbell S. Nitric oxide in the endometrium. Hum Reprod Update 1998; 4(5): 565-9.
[http://dx.doi.org/10.1093/humupd/4.5.565] [PMID: 10027610]
[64]
Kulmacz RJ, Wang LH. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem 1995; 270(41): 24019-23.
[http://dx.doi.org/10.1074/jbc.270.41.24019] [PMID: 7592599]
[65]
Landino LM, Crews BC, Gierse JK, Hauser SD, Marnett LJ. Mutational analysis of the role of the distal histidine and glutamine residues of prostaglandin-endoperoxide synthase-2 in peroxidase catalysis, hydroperoxide reduction, and cyclooxygenase activation. J Biol Chem 1997; 272(34): 21565-74.
[http://dx.doi.org/10.1074/jbc.272.34.21565] [PMID: 9261177]
[66]
Musee J, Marnett LJ. Prostaglandin H synthase-2-catalyzed oxygenation of 2-arachidonoylglycerol is more sensitive to peroxide tone than oxygenation of arachidonic acid. J Biol Chem 2012; 287(44): 37383-94.
[http://dx.doi.org/10.1074/jbc.M112.381202] [PMID: 22942274]
[67]
Mohan D, Rossiter H, Watz H, et al. Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: A randomised control trial. Thorax 2023; 78(3): 258-66.
[http://dx.doi.org/10.1136/thorax-2021-218360] [PMID: 36283827]
[68]
D’Arcangelo D, Gaetano C, Capogrossi MC. Acidification prevents endothelial cell apoptosis by Axl activation. Circ Res 2002; 91(7): e4-e12.
[http://dx.doi.org/10.1161/01.RES.0000036753.50601.E9] [PMID: 12364394]
[69]
Sun WS, Misao R, Iwagaki S, Fujimoto J, Tamaya T. Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases, Axl and Sky, in human uterine endometrium and ovarian endometriosis. Mol Hum Reprod 2002; 8(6): 552-8.
[http://dx.doi.org/10.1093/molehr/8.6.552] [PMID: 12029073]
[70]
Zygmuntowicz A, Markiewicz W, Grabowski T, Burmańczuk A, Vyniarska A, Jaroszewski JJ. Quercetin affects uterine smooth muscle contractile activity in gilts. PLoS One 2021; 16(7): e0252438.
[http://dx.doi.org/10.1371/journal.pone.0252438] [PMID: 34270573]
[71]
Jafari Khorchani M, Samare-Najaf M, Abbasi A, Vakili S, Zal F. Effects of quercetin, vitamin E, and estrogen on metabolic-related factors in uterus and serum of ovariectomized rat models. Gynecol Endocrinol 2021; 37(8): 764-8.
[http://dx.doi.org/10.1080/09513590.2021.1879784] [PMID: 33525940]
[72]
Hu W, Zhang J, Wang H, et al. Protective effects of isorhamnetin against H2O2-induced oxidative damage in HaCaT cells and comprehensive analysis of key genes. Sci Rep 2023; 13(1): 2498.
[http://dx.doi.org/10.1038/s41598-023-27575-7] [PMID: 36781904]
[73]
Oh SH, Lee SE, Yoon JW, et al. Isorhamnetin improves in vitro maturation of oxidative stress-exposed porcine oocytes and subsequent embryo development. Zygote 2023; 31(1): 14-24.
[http://dx.doi.org/10.1017/S0967199422000399] [PMID: 36683392]
[74]
Park S, Lim W, Bazer FW, Song G. Naringenin induces mitochondria-mediated apoptosis and endoplasmic reticulum stress by regulating MAPK and AKT signal transduction pathways in endometriosis cells. Mol Hum Reprod 2017; 23(12): 842-54.
[http://dx.doi.org/10.1093/molehr/gax057] [PMID: 29121349]
[75]
Lim R, Barker G, Wall CA, Lappas M. Dietary phytophenols curcumin, naringenin and apigenin reduce infection-induced inflammatory and contractile pathways in human placenta, foetal membranes and myometrium. Mol Hum Reprod 2013; 19(7): 451-62.
[http://dx.doi.org/10.1093/molehr/gat015] [PMID: 23475986]
[76]
Ijuin T, Takenawa T. Role of phosphatidylinositol 3,4,5-trisphosphate (PIP3) 5-phosphatase skeletal muscle- and kidney-enriched inositol polyphosphate phosphatase (SKIP) in myoblast differentiation. J Biol Chem 2012; 287(37): 31330-41.
[http://dx.doi.org/10.1074/jbc.M112.388785] [PMID: 22815484]
[77]
Wang S, Gu Y, Cao X, et al. The identification and validation of target genes of IGFBP3 protein in sheep skeletal muscle cells. Anim Biotechnol 2023; 34(9): 4580-7.
[http://dx.doi.org/10.1080/10495398.2023.2174875] [PMID: 36794322]
[78]
Ding JF, Sun H, Song K, et al. IGFBP3 epigenetic promotion induced by METTL3 boosts cardiac fibroblast activation and fibrosis. Eur J Pharmacol 2023; 942: 175494.
[http://dx.doi.org/10.1016/j.ejphar.2023.175494] [PMID: 36657656]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy